Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
265 result(s)
Ellipta inhaler
27-11-2015
Ellipta inhaler information for UK healthcare professionals including getting started, how to use the Ellipta inhaler and top tips for your patients.
Homepage
GSKpro is exclusively created for healthcare professionals to provide GSK product related information, services and support.
Therapy areas
GSK UK therapy areas page allows healthcare professionals to find GSK product information by therapy area.
Request a contact
Contact us form for UK healthcare professionals to contact GSK
Contact us
GSK UK contact page for healthcare professionals
Video Testimonials: I've Seen Meningitis
Video testimonials from healthcare professionals about the impact of meningitis
Requip & Adartrel (Ropinirole) artwork change | GSKpro
Information for changes to the colour of the ink on both the cartons and blister packs of Requip and a blister pack of Adartrel.
Medicines management and optimisation
Access bespoke financial and prescribing data for your health economy. Identify variability, track and optimise your implementation projects
Respiratory
Overview of Asthma and COPD
Ordering and delivery
Find out how to set up an account and start ordering GSK vaccines.
Varilrix
Varilrix – Chickenpox/varicella vaccine product information to support UK healthcare professionals
Seretide inhaler technique and safety
Videos and materials to help you ensure your patients are using their Seretide Accuhaler and Evohaler correctly.
Adartrel
Adartrel (ropinirole hydrochloride) - links to the summary of product characteristics, patient information leaflet and supply information to support UK healthcare professionals.
COPD
Overview of COPD
Oncology Expert Insights
Expert opinion on ovarian cancer treatment to support UK healthcare professionals
Sitemap
GlaxoSmithKline (GSK) UK healthcare professional website site map.
Report Adverse Event
Form for UK healthcare professionals to report an adverse event related to a GSK product
GSK Highlights from ATS 2020 | GSKpro
GSK Highlights from The American Thoracic Society (ATS) Congress 2020
Home | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Vaccines
GSK UK information about our vaccines and disease awareness campaigns
DECTOVA▼
Zanamivir IV</br> Influenza
COPD expert perspectives
Watch GSK Global Medical Experts approach key issues in COPD treatment, offering solutions for UK healthcare professionals.
Asthma expert perspectives
Watch GSK Global Medical Experts approach key issues in asthma treatment, offering potential solutions for you and your patients
Asthma
Overview of Asthma
Ellipta critical error studies in asthma
Information about the benefits of GSK's Ellipta inhaler for UK healthcare professionals to support their asthma patients
Ellipta inhaler products
Ellipta inhaler product information for UK healthcare professionals including an overview of the medicines available in the Ellipta device.
Ellipta critical error studies in COPD
Information about the benefits of GSK's Ellipta inhaler for UK healthcare professionals to support their COPD patients
Patient stories | Seretide (salmeterol/fluticasone propionate)
Patient stories with Seretide Evohaler (salmeterol/fluticasone propionate)
Cost | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) price information to support UK healthcare professionals
Dose & Device | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) dosing and device information to support UK healthcare professionals
Guidelines |Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)| GSKPro
Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Identifying patients | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Safety Information | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
HRQoL | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Lung Function | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) I COPD I GSKPro
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Efficacy
Trelegy Ellipta is a Triple Therapy indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA.
Molecules | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Efficacy | Nucala (mepolizumab)
Read the clinical data about Nucala (mepolizumab).
Nucala (meplizumab) | Severe eosinophilic asthma
Learn more about Nucala (mepolizumab) as an add-on treatment for patients with severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Resources | Nucala (mepolizumab)
View other resources to support you and your patients using Nucala (mepolizmab) as an add on treatment for adults, adolescents and children over 6 years old with severe refractory eosinophilic asthma.
Expert Perspectives | Nucala (mepolizumab)
See what the experts have to say about Nucala (mepolizumab).
Safety Information | Nucala (mepolizumab)
See the safety profile of Nucala (mepolizumab) in adults and adolescents.
Paediatric Patients | Nucala (mepolizumab)
See the data behind and safety profile of Nucala (mepolizumab) in paediatric patients with severe asthma.
Identifying Patients | Nucala (mepolizumab)
Understand how to identify which patients with severe asthma are suitable for treatment with Nucala (mepolizumab) as an add-on treatment.
Dosing & Administration | Nucala (mepolizumab)
Nucala (mepolizumab) can be administered at home or in clinic. Read more about dosing and administration here.
Zejula▼
Niraparib
Products
GSK product information for UK healthcare professionals
GSK support for healthcare professionals in response to COVID-19
Information for healthcare professionals on GSK’s response to COVID-19, where to find support and relevant resources.
GSK Highlights from ERS 2020 | GSKpro
GSK Highlights from European Respiratory Congress 2020
Safety Information | Nucala (mepolizumab)
See the safety profile of Nucala (mepolizumab) in adults and adolescents.
Dosing & Administration | Nucala (mepolizumab)
Nucala (mepolizumab) can be administered at home or in clinic. Read more about dosing and administration here.
Resources | Nucala (mepolizumab)
View other resources to support you and your patients using Nucala (mepolizmab) as an add on treatment for adults, adolescents and children over 6 years old with severe refractory eosinophilic asthma.
Identifying Patients | Nucala (mepolizumab)
Understand how to identify which patients with severe asthma are suitable for treatment with Nucala (mepolizumab) as an add-on treatment.
Expert Perspectives | Nucala (mepolizumab)
See what the experts have to say about Nucala (mepolizumab).
Nucala (meplizumab) | Severe eosinophilic asthma
Learn more about Nucala (mepolizumab) as an add-on treatment for patients with severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Discontinued products | GSK Pro
Discontinued products
Paediatric Patients | Nucala (mepolizumab)
See the data behind and safety profile of Nucala (mepolizumab) in paediatric patients with severe asthma.
Supply
Information to be provided to Healthcare Professionals on GSK’s medicines and vaccines supply availability
Products
GSK product information for UK healthcare professionals
FAQ | Supply | GSKpro
Frequently asked questions around the supply and availability of GSK medicines and vaccines.
Efficacy | Nucala (mepolizumab)
Read the clinical data about Nucala (mepolizumab).
No results. Why not try:
- Checking the spelling of the search term
- Trying a different search term
- Resetting or revising the filter settings (if you used filters to do this search)
Show more
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
